Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Physician Assistant Studies Student
Scholarship

Student Dissertations, Theses and Papers

2016

Is Pancrelipase Delayed Release Capsule (Creon)
Safe for Use in Patients’ ≥7 Years Old Who Suffer
From Pancreatic Insufficiency Due to Cystic
Fibrosis?
Iman Shamloul
Philadelphia College of Osteopathic Medicine, imansh@pcom.edu

Follow this and additional works at: http://digitalcommons.pcom.edu/pa_systematic_reviews
Part of the Digestive System Diseases Commons
Recommended Citation
Shamloul, Iman, "Is Pancrelipase Delayed Release Capsule (Creon) Safe for Use in Patients’ ≥7 Years Old Who Suffer From Pancreatic
Insufficiency Due to Cystic Fibrosis?" (2016). PCOM Physician Assistant Studies Student Scholarship. 302.
http://digitalcommons.pcom.edu/pa_systematic_reviews/302

This Selective Evidence-Based Medicine Review is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Physician Assistant Studies Student Scholarship by an authorized
administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

Is Pancrelipase Delayed Release Capsule (Creon) Safe for Use in
Patients’ ≥7 Years Old Who Suffer From Pancreatic
Insufficiency Due to Cystic Fibrosis?

Iman Shamloul, PA-S
A SELECTIVE EVIDENCE BASED MEDICINE REVIEW
In Partial Fulfillment of the Requirements For
The Degree of Master of Science
In
Health Sciences – Physician Assistant
Department of Physician Assistant Studies
Philadelphia College of Osteopathic Medicine
Philadelphia, Pennsylvania
December 18, 2015

ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
Pancrelipase Delayed Release Capsule (Creon) is safe for use in patients’ ≥7 years old who
suffer from pancreatic insufficiency due to cystic fibrosis.
Study Design: Systemic review of 3 English language primary studies, published between 20002010.
Data Sources: Two double blind randomized controlled trials (RCTs) as well as an open label
phase study with a double blind phase comparing the safety of Pancrelipase Delayed Release
Capsule (Creon) in treating pancreatic insufficiency in those suffering from Cystic Fibrosis.
These studies were found using Cochrane Systematic Reviews and PubMed.
Outcomes Measured: The outcomes of each study measured the safety and tolerability of Creon
by monitoring vital signs, weight, BMI, safety laboratory values, and adverse events. Adverse
events were tracked in all studies.
Results: Graff et al demonstrated that for every three participants who took Creon, there was one
fewer incidence of Treatment Emergent Adverse Events (TEAE’s) than in the group of
participants taking the placebo. TEAE’s were reported in 5 patients (29.4%) while taking Creon
and in 9 patients (53.6%) while receiving the placebo. There were also no discontinuations due
to treatment adverse events and no serious adverse events noted during the trial. Trapnell et al
demonstrated that for every four participants who took Creon there was one fewer incidence of
TEAE’s than in the group of participants taking the placebo. Stern et al demonstrated that during
the double blind phase in both the adult and pediatric/adolescent studies, higher percentages of
placebo-treated patients (67% and 70% respectively) reported treatment emergent adverse events
than Creon treated patients (39% and 61% respectively).
Conclusion: Creon does appear to be safe and tolerable for those over the age of 7 suffering
from pancreatic insufficiency due to cystic fibrosis. The TEAE’s reported in each study proved
the tolerance of Creon to surpass that of other treatment modalities. These studies also address
the other benefits of Creon in allowing for significant improvements in stool fat, weight, and
nitrogen and a significant reduction in daily stool frequency. Although these are promising
results more RCTs must be conducted with wider age groups in order to compare the safety of
Creon.
Key words: Creon, Cystic Fibrosis, Pancreatic Insufficiency
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INTRODUCTION

Cystic fibrosis is a hereditary disorder affecting the exocrine glands causing the
production of abnormally thick mucus, leading to the blockage of pancreatic ducts, intestines,
and bronchi and often resulting in respiratory infections.1 Exocrine pancreatic insufficiency (EPI)
is defined as the lack of digestive enzymes secreted by the pancreas in association with diseases
such as cystic fibrosis which leads to maldigestion, with resultant malabsorption of fat, protein,
and fat soluble vitamins which ultimately leads to malnutrition.2 Approximately 85% of patients
diagnosed with cystic fibrosis also have EPI. The symptoms begin in newborns shortly after birth
and increase throughout infancy.2 Approximately 90% of patients with EPI are treated with
pancreatic enzyme replacement therapy to maintain adequate nutrition.2 If EPI is left untreated,
the subsequent malnutrition and debilitating symptoms may lead to poor growth, poor weight
gain, and failure to thrive especially for those with cystic fibrosis.2
Cystic fibrosis is the most common autosomal genetic disease among white persons and
has a prevalence of 1 in 2,500 newborn infants.3 The only risk factor for cystic fibrosis is a
family history of the condition. The mean annual healthcare cost for treating cystic fibrosis in the
United States is $48,098 which is more than 22 times the average of $2,172 for people without
cystic fibrosis.4 Medical expenditures for people with cystic fibrosis increase with age through
childhood and plateau during and after the teenage years.4
A study shows that adults with cystic fibrosis average about 12 office visits per year.
Despite the monthly contact with physicians, 33% of patients have at least one inpatient stay per
year.5 Individuals with cystic fibrosis have mean annual expenditures for inpatient care that are
35 times higher ($16, 545 vs. $467) than those for people without cystic fibrosis.4 This was due
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primarily to the greater number of inpatient admissions among those in the cystic fibrosis group.
The average expenditure for outpatient visits are 10 times higher ($13,092 vs. $1,267) for those
with cystic fibrosis than individual’s without.4 Not only are hospital admissions and healthcare
costs higher for those with cystic fibrosis, but one of the biggest monetary burdens is prescribed
medications. The average annual expenditures for prescribed medications were 42 times higher
($18,461 vs. $437) among those with cystic fibrosis.4
Cystic fibrosis is an autosomal recessive disease caused by abnormalities of the cystic
fibrosis transmembrane conductance regulator (CFTR) chloride conductance channel and affects
the function of the exocrine glands in multiple organs, including the lungs, liver, pancreas,
intestines, and skin.5 The disease is characterized by malabsorption, gastrointestinal
abnormalities, infertility, and severe progressive sinopulmonary disease.5 Differences in disease
patterns seen in individuals and families probably result from the combined effects of the
particular mutation and various, but still unknown, factors in the patient and his or her
environment.6 Despite the great advances in research, there is still no cure for cystic fibrosis due
to these genetic changes and mutations.
There are numerous treatment options for individuals suffering from cystic fibrosis, each
of which targets a different symptomology caused by the disease. The main treatments for lung
problems in people with cystic fibrosis focus on antibiotics for infections of the airways, chest
physical therapy, and exercise. The antibiotics used are: Tobramycin, Colistin, and
Azithromycin.7 Chest physical therapy requires the individual to pound their chest and back over
and over in order to dislodge the mucus within their lungs. Patients are encouraged to perform
aerobic exercise in order to loosen their mucus and encourage coughing to clear the mucus build
up in the lungs. Surgeries are a common occurrence for those suffering from cystic fibrosis and
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range from nasal polyp removal to lung transplants. One of the hardest components of the
disease to treat are digestive complications. Patients are treated with oral pancreatic enzymes to
help them digest fats and proteins and to assist in the absorption of vitamins.
Although there are several drugs that aid those with EPI, Creon has been approved for
those with cystic fibrosis. Pancreatic enzyme replacement therapy is critical for adequate
nutrition in patients with cystic fibrosis with EPI. Thus far, numerous studies have been
conducted and results show that Creon is a safe treatment for EPI due to cystic fibrosis. Creon
allows patients significant improvements in stool fat, weight gain, and absorption of nutrients
due to its ability to break down fats, proteins, and carbohydrates.

OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is Pancrelipase
Delayed Release Capsule (Creon) safe for use in patients’ ≥7 years old who suffer from
pancreatic insufficiency due to cystic fibrosis.”

METHODS
The criteria used for the selection of the 3 studies included that patients be either male or
female over the age of 7 with cystic fibrosis causing exocrine pancreatic insufficiency. The
studies involved the interventional use of either Creon 12,000 Units or 24,000 units. The
comparison groups in the two RCTs received either Creon or a visually matched placebo. In the
double blind phase study a group was given Creon while a subgroup was given either Creon or a
placebo. The outcomes measured in the 3 studies included the safety and tolerability of Creon for
the treatment of exocrine pancreatic insufficiency due to cystic fibrosis using the incidence of
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treatment emergent adverse events (TEAEs) for statistical analysis. The three studies included
consist of two randomized, double blind, placebo controlled studies, two period crossover
clinical trials (RCTs) and one open label phase study with a double blind phase.
Keywords used to search for the articles included “cystic fibrosis”, “Creon”, and
“pancreatic insufficiency”. All articles were originally published in peer-reviewed journals in the
English language. Data was researched and collected by the author using articles from 20002010 in PubMed and the Cochrane library. Articles were selected based on relevance to the
clinical question and whether they included patient oriented evidence that matters (POEMS). All
articles chosen for this review were peer-reviewed and published in well-known journals such as
Journal of Clinical Therapeutics, The American Journal of Gastroenterology, and the Journal of
Cystic Fibrosis. Inclusion criteria consisted of the requirement that studies that were RCTs or
clinical trials published after 1996 in which no other systematic reviews, meta-analysis, or
review article was found on the Cochrane database answering the same question with additional
criteria found in Table 1. Exclusion criteria included studies in which patients under 7 years old
were utilized. The statistics used to evaluate patient outcomes included p values, RRI, ARI, CI,
and NNH. The demographics and characteristics of the individuals included in these studies are
displayed in table 1.
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Table 1 - Demographics & Characteristics of included studies (Table 1)
Study

Type

# Pts

Age
(yrs)
7 to 11
years
old

Graff,
2010
(2)

RCT

17

Stern,
2000
(8)

Open
label

97

>18
years of
age and
between
7 and 18
years of
age

Trapnell,
2009
(9)

RCT

34

12 years
of age
and
older

Inclusion Criteria

Exclusion Criteria

W/D

Interventions

-confirmed diagnosis of CF
2 positive sweat tests and/or
disease causing mutations
detected on CF
transmembrane conductance
regulator gene analysis
-confirmed diagnosis of
enzymatic pancreatic
insufficiency (EPI) defined
as a coefficient of fat
absorption (CFA) <70%
without pancreatic enzyme
supplementation or as
human fecal elastase
<50ug/g (measured within
the past 12 months)
-must have been receiving
treatment with a
commercially available
PERT product as a stable
dose for >3 months
-a diagnosis of CF
documented by sweat
chloride results (>70) and
clinical symptoms of
exocrine pancreatic
insufficiency with a history
of steatorrhea
-patients must have been
stabilized on a diet and dose
of pancreatic enzyme
supplementation
- a diagnosis of CF
(confirmed by 2 positive
chloride sweat tests and/or
CFTR gene analysis) and
EPI (confirmed by either a
coefficient of fat absorption
(CFA) <70% without
supplementation or fecal
elastase <50 ub/g stool
within the past 12 months)
-receiving treatment with a
commercially available
pancreatic enzyme product

-if patient had severe
medical conditions that
limit participation
-if they had undergone
any recent major surgery
-Ileus or acute abdomen
malignancy of the
digestive tract
(excluding pancreatic
cancer), HIV, celiac/
Chron’s disease
-known allergy to
Pancrelipase or the
inactive ingredients in
Pancrelipase delayed
release capsules, or
exposure to an
experimental drug
within 30 days of the
start of the study

1

Creon 12,000
units

-if a patient had extreme
cachexia, severe acute or
chronic pulmonary
disease, or were using
other gastrointestinal
medications or
medications affecting
the gastrointestinal tract
other than oral
pancreatic enzymes

21

Creon and high
fat diet

-if they had an ileus or
acute abdomen, distal
ileal obstruction
syndrome within 6
months of enrolment,
gastrointestinal
malignancy within 5
years of enrollment, a
history of pancreatitis or
fibrosing colonopathy or
known infection with
HIV

2

Creon 24,000
units
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OUTCOMES MEASURED
All of the outcomes measured were POEMS related to the safety and tolerability of Creon
for the treatment of pancreatic insufficiency in those with cystic fibrosis. Outcomes were
measured in a variety of ways and included vital signs, physical examination, weight, BMI,
safety laboratory values, and adverse events.2, 8, 9 The safety of Creon was measured by treatment
emergent adverse events (TEAEs) reported by the patients.8, 9, 10 The TEAEs monitored were
gastrointestinal disorders, nervous system disorders, respiratory disorders, and skin/subcutaneous
tissue disorders.2, 8, 9 Secondary efficacy outcomes were also assessed. These include the
coefficient of nitrogen absorption (CAN), stool fat, stool weight, and clinical symptomatology.2,
8, 9

Laboratory analyses using standard procedures were performed at Mayo Clinical Trial

Services.2, 8, 9

RESULTS
The three studies chosen evaluated the safety of Creon for the treatment of pancreatic
insufficiency in individuals ≥7 years old suffering from cystic fibrosis. Two double blind
randomized controlled trials (RCTs) as well as an open label phase study with a double blind
phase were chosen for analysis.
The study conducted by Graff et al consisted of twenty three individuals, sixteen of
whom completed the study. Inclusion and exclusion criteria for the study can be found in Table
1.Each period during the 2-period crossover consisted of the patients receiving either Creon
12,000 units or the identical placebo capsules for a total of five days. A variety of safety
measures were monitored during the stud. These included: vital signs, physical examinations,
standard laboratory safety tests (hematology and biochemistry), and adverse events. Treatment
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emergent adverse events were reported in 5 patients (29.4%) during receipt of Creon and in 9
patients (56.3%) during receipt of placebo; these were predominantly gastrointestinal events.
There were no discontinuations due to treatment emergent adverse events and no serious adverse
events. Creon was also shown to provide significant improvements in stool fat, weight, and
nitrogen and a significant reduction in daily stool frequency as compared with the placebo (p
<0.001). The NNH was calculated to be -3 (Table 2) which indicates that for every three
participants who took Creon, there was one fewer incidence of TEAE’s than in the group of
participants taking the placebo.2

Table 2. Analysis of Numbers Needed to Harm for Creon Use
Graff (2010)

CER

EER

RRI

ARI

NNH

56.3%

29.4%

-48%

-26.9%

-3

The study conducted by Trapnell et al consisted of thirty four individuals, thirty two of
whom completed the study. Inclusion and exclusion criteria for the study can be found in Table
1. Each period during the 2-period crossover each period consisted of the patients receiving
either Creon 24,000 units or the identical placebo capsules for a total of five days. A variety of
safety measures were monitored during the study. These included: vital signs, physical
examinations, standard laboratory safety tests (hematology and biochemistry), and adverse
events. Physical examinations were performed during screening and at the end of each crossover
period. Laboratory safety tests were performed during screening, at the end of the first crossover
period, and at the beginning and end of the second crossover period. Treatment emergent adverse
events and treatment related TEAEs had a lower overall incidence during Creon treatment than
during placebo treatment (43.8% vs. 64.5%). Analysis of adverse events did not reveal any
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TEAEs with a greater clinically meaningful incidence in the Creon group compared with the
placebo group, and no cases of hypersensitivity were reported. Creon was also shown to provide
significant improvements in stool fat, weight, and nitrogen and a significant reduction in daily
stool frequency as compared with the placebo (p <0.001 for all). The NNH was calculated to be 4 (Table 3) which indicates that for every four participants who took Creon, there was one fewer
incidence of TEAE’s than in the group of participants taking the placebo.9

Table 3. Analysis of Numbers Needed to Harm for Creon Use
Trapnell (2009)

CER
64.5%

EER
43.8%

RRI
-32.1%

ARI
-20.7%

NNH
-4

The study conducted by Stern et al consisted of ninety seven individuals, seventy four of
whom completed the study. Of those seventy four patients, thirty six were adults and thirty eight
were pediatrics/adolescents. Inclusion and exclusion criteria for the study can be found in Table
1. During the open label phase study and the double blind phase study patients received either
Creon or the identical placebo capsules for a total of five to seven days. Tolerance was assessed
by physical examination, adverse events, vital signs, urinalysis, and serum biochemistry and
hematology evaluations. During the open label phase, 52% of the adult patients and 64% of the
pediatric/adolescent patients reported at least one treatment emergent adverse event. During the
double blind phase in both the adult and pediatric/adolescent studies, higher percentages of
placebo-treated patients (67% and 70% respectively) reported treatment emergent adverse events
than Creon treated patients (39% and 61% respectively). Creon was also shown to provide
significant improvements in stool fat, weight, and nitrogen and a significant reduction in daily

Creon Safety for Cystic Fibrosis 9
Shamloul
stool frequency as compared with the placebo (p <0.001 for all). The NNH could not be
calculated for this study due to the lack of control throughout the duration of the trail.8

DISCUSSION
The results from these studies demonstrate that Creon therapy is a safe and effective
treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis. Although none of
the studies compared Creon to any other EPI drug, these early studies show promising results in
terms of efficacy and safety. In all three studies the adverse events were minimal and the
reported TEAE’s proved to be minuscule. Creon treated patients demonstrated significantly
superior results compared with placebo treated patients for coefficient of fat absorption, stool
frequency, stool consistency, and coefficient of nitrogen absorption.2, 8, 9
Although these studies yielded important results, there were limitations that need to be
addressed. The number of patients employed in each study was very low. By enrolling more
participants results gathered are more efficacious. In addition, trials need to be completed with
individuals suffering from cystic fibrosis who are under the age of seven. This will allow for the
investigation of the efficacy of Creon in pediatric and neonatal patients. Another limitation that
can be addressed is the duration of the studies. All three studies lasted only five to seven days. In
order to gain better results, longitudinal analyses must be conducted.
Creon is also used for other conditions that cause pancreatic insufficiency. These
conditions include chronic pancreatitis, cystic fibrosis, pancreatic cancer, post pancreatectomy,
and post- gastrointestinal bypass surgery.10 Due to the wide use of Creon, it is commonly
covered by most insurance companies. There are also Patient Assistance Programs that help
supply the drug for free or at a reduced cost for its customers. However, for those individuals
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without insurance the cost of 90 capsules of Creon totals about $500.11 Such an elevated cost can
truly hinder a patient’s ability to afford a vital medication for their wellbeing.

CONCLUSION
This review and chosen studies show that Creon is a safe treatment for pancreatic
insufficiency in individuals with cystic fibrosis who are ≥7 years of age. No serious or life
threatening adverse events were reported related to the use of Creon during these studie. None of
the studies reported any deaths when the use of Creon even when extremely high doses (24,000
Units).
Due to the limited amount of studies, small sample sizes, and very few comparison
studies, future studies are needed to directly compare Creon with other EPI drugs in order to test
efficacy and safety. Also, future research should include longer treatment durations to more
definitively evaluate the benefits and risks of treating cystic fibrosis patients with Creon.

REFERENCES
1. What is Cystic Fibrosis? About Cystic Fibrosis . Available at: https://www.cff.org/what-iscf/aboutcysticfibrosis/?gclid=cjwkeajwv8iwbrc35e8apqwcesjab8khp93fno9ifbqmmmhwkwjnqs9
usli8ln1jbogupl3io1mrocs9rw_wcb. Accessed May 2015.
2. Graff GR, Maguiness K, McNamara J, et al. Efficacy and tolerability of a new formulation of
pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic
insufficiency and cystic fibrosis: A multicenter, randomized, double-blind, placebo-controlled,
two-period crossover, superiority study. Clin Ther. 2010;32(1):89-103.
3. O’Sullivan A, Sullivan J, Higuch K, Montgomery B. Health Care Utilization & Costs For
Cystic Fibrosis Patients With Pulmonary Infections. Managed Care 2011;20(2):37–44.
4. Dewitt EM, Grussemeyer CA, Friedman JY, et al. Resource Use, Costs, and Utility Estimates
for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data
Collected Alongside a 48-Week Multicenter Clinical Trial. Value in Health 2012;15(2):277–283.
5. Ouyang L, Grosse SD, Amendah DD, Schechter MS. Healthcare expenditures for privately
insured people with cystic fibrosis. Pediatr Pulmonol. 2009;44(10):989-96.
6. Cystic Fibrosis. Available at: http://www.healingwell.com/library/cysticfibrosis/info2.asp.
Accessed December 11, 2015.
7. How is Cystic Fibrosis Treated? Available at: http://hospitals.unm.edu/cf/cf_treatment.shtml.
Accessed May 2015.
8. Stern RC, Eisenberg JD, Wagener JS, et al. A comparison of the efficacy and tolerance of
pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical
exocrine pancreatic insufficiency. Am J Gastroenterol. 2000;95(8):1932-1938.
9. Trapnell BC, Maguiness K, Graff GR, Boyd D, Beckmann K, Caras S. Efficacy and safety of
creon 24,000 in subjects with exocrine pancreatic insufficiency due to cystic fibrosis. J Cyst
Fibros. 2009;8(6):370-377.
10. Creon 5. Available at: http://www.webmd.com/drugs/2/drug-10705/creon-5-oral/details.
Accessed December 11, 2015.
11. Creon Cost. Available at: http://www.goodrx.com/creon. Accessed December 11, 2015.

